ZYDUS LIFESCIENCES:

CO. RECEIVES APPROVAL FOR PHASE III TRIAL OF DESIDUSTAT IN SICKLE CELL DISEASE PATIENTS IN COLLABORATION WITH ICMR; PHASE II TRIAL MET PRIMARY ENDPOINTS; DESIDUSTAT HAS ORPHAN DRUG DESIGNATION FROM US FDA. $ZYDUSLIFE